Evidence map›Paper›PMID 36119841›Full record

ArticleAmerican journal of cancer research2022

Small extracellular vesicle-associated miR-6068 promotes aggressive phenotypes of prostate cancer through miR-6068/HIC2/SIRT1 axis.

Mohamed S A Gaballah, Hamdy E A Ali, Zeinab A Hassan, Shahenda Mahgoub, Hamid I Ali, Johng S Rhim, Mourad Zerfaoui, Khalid A El Sayed, David Stephen, Paul W Sylvester and 1 more

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Diagnostic value of [Frontiers in oncology · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Mohamed S A GaballahDepartment of Pharmaceutical Sciences, Rangel College of Pharmacy, Texas A&M University College Station 77843, USA.
Hamdy E A AliDepartment of Pharmaceutical Sciences, Rangel College of Pharmacy, Texas A&M University College Station 77843, USA.
Zeinab A HassanDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Helwan University Helwan, Cairo 11795, Egypt.
Shahenda MahgoubDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Helwan University Helwan, Cairo 11795, Egypt.
Hamid I AliDepartment of Pharmaceutical Sciences, Rangel College of Pharmacy, Texas A&M University College Station 77843, USA.
Johng S RhimDepartment of Surgery, Uniformed Services University of The Health Sciences Bethesda, MD 20814, USA.
Mourad ZerfaouiDepartment of Surgery, Tulane University School of Medicine New Orleans, LA 70112, USA.
Khalid A El SayedSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe Monroe, LA 71203, USA.
David StephenDepartment of Pathology, Edward Via College of Osteopathic Medicine Auburn, LA 36832, USA.
Paul W SylvesterSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe Monroe, LA 71203, USA.
Zakaria Y Abd ElmageedDepartment of Pharmaceutical Sciences, Rangel College of Pharmacy, Texas A&M University College Station 77843, USA.
Helwan University · EGUniversity of Louisiana at Monroe · USTexas A&M University · USEdward Via College of Osteopathic Medicine · USTulane University · USUniformed Services University of the Health Sciences · US

Funding

The role of exRNA in Health Disparity of Prostate CancerR21CA194750 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI ABD ELMAGEED, ZAKARIA · 2015 to 2016
$350k
NCI NIH HHS R21 CA194750
6 · The paper itself

Abstract

Early diagnosis and treatment of patients with aggressive prostate cancer (PCa) remains a clinically unmet need. We aimed to determine the levels of small extracellular vesicle (sEV)-associated microRNAs (miRs); miR-4737, miR-6068, and miR-6076 in a large panel of PCa cells and delineate the biological significance of miR-6068 in promoting PCa cells. sEVs were isolated from the conditioned medium of PCa cells, followed by RNA extraction and quantitative Real-Time PCR analysis. Functional assays were performed, and the protein expression of hypermethylated in cancer 2 (HIC2), as a potential miR-6068 target gene, was evaluated in PCa tissues by immunohistochemistry. sEV-associated miR-6068, miR-4737, and miR-6076 levels displayed large and significant differences compared to normal cells. miR-6068 was explicitly upregulated in sEV of PC-3 and CWR-R1ca cells (P<0.010). Suppression of miR-6068 in CWR-R1ca cells decreased cell proliferation, colony formation, and cell migration. In contrast, upregulation of miR-6068 in RC77T/E cells decreased HIC2 levels and increased cell aggressive phenotypes. The overexpression of HIC2 in PCa tissues was primarily observed in the cytoplasm compared to benign prostatic hyperplasia (BPH) and normal tissues (P<0.0001). This study confirms the differential packaging of miR-4737, miR-6068, and miR-6076 in sEVs of PCa cells. MiR-6068 promotes PCa cells to acquire aggressive phenotypes by inhibiting the HIC2/Sirtuin 1 (SIRT1) axis.

Indexed as

functional assaysHIC2miR-6068Prostate cancersmall extracellular vesicles

Identifiers

PMID36119841
PMCPMC9442005
OpenAlexW4296322784

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.